SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it kicks off public deliveries for the R2 midsize SUV, with investors intensely debating whether the launch marks a pivotal shift toward profitability or just another "sell-the-news" event. The community is sharply divided between those cheering the R2's positive reviews and partnerships with firms like Uber, and those frustrated by continued cash burn, management's communication style, and the stock's persistent volatility.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing high volatility as investors weigh a aggressive multi-year production ramp for AI-driven data center transceivers against steep valuation premiums and recent insider selling. While bullish sentiment focuses on the company's vertical integration and ability to navigate supply chain bottlenecks, bearish voices highlight execution risks and concerns over whether current price levels have already fully priced in long-term growth expectations.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining momentum as market participants increasingly highlight its status as an established meme with original IP rights and a growing community presence. Investors are actively drawing parallels to past major market cycles while debating its potential for future growth alongside other prominent meme-sector assets.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is gaining significant traction due to its expanded role in institutional payment infrastructure, highlighted by recent integrations with banking giants and the growth of tokenized real-world assets on the XRP Ledger. Community discourse remains highly active, fueled by the launch of spot ETFs and growing optimism regarding the clarity of digital asset regulations.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is under intense market scrutiny following an FDA clinical hold placed on its RGX-111 and RGX-121 gene therapy programs due to a tumor found in a trial participant. The community is actively debating the implications for the February 8 PDUFA date for RGX-121, with many fearing a delay or rejection despite the company's efforts to advance its broader pipeline.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders rotate back into AI and IoT-linked tokens, with the community closely tracking potential ecosystem expansion and technical breakout patterns. Sentiment remains divided between long-term holders betting on utility-driven adoption in Japan and skeptical traders who view recent price action as speculative volatility.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense discussion driven by its high volatility and community debates regarding its long-term viability versus its identity as a meme-heavy speculative asset. Investors are actively tracking its correlation with other memecoins and comparing it to broader market trends as sentiment remains sharply divided between those calling for a breakout and those warning of a total collapse.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory path for AXPAXLI, with community discussions heavily focused on the company's strategy for NDA submission based on single-trial data and potential M&A interest. While some shareholders remain optimistic about a buyout or partnership following strong clinical data, others are raising concerns over competitive legal threats, market volatility, and the timeline for upcoming investor presentations.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

Dogwifhat (WIF) is currently trending as the community expresses deep frustration over persistent price stagnation and repetitive sell-offs, leading to heated debates between long-term holders and bearish traders. While some investors are actively accumulating and pointing to optimistic long-term price projections and the potential for a broader altcoin market recovery, others remain skeptical, citing a perceived lack of project development and utility.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following a successful Phase 3 trial readout and subsequent equity offering, which has sparked intense debate over the stock's valuation and potential for a short squeeze. While bulls point to the transformative clinical results for Lonvoguran Ziclumeran as evidence of a multi-billion dollar market opportunity, skeptics remain focused on the dilutive impact of the capital raise and the stock's recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus recommendation of "Hold" by the eleven ratings firms that are covering the firm, MarketBeat.com reports. One...

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astrias stockholders held on January 21, 2026, Astrias stockholders voted to approve the acquisition of Astria...

Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Increases By 37.9%

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 5,752,164 shares, a growth of...

Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened

Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average - Should You Sell...

BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference

BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, highlighting continued momentum for its hereditary angioedema (HAE) franchise, a...

Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to...

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus recommendation of "Hold" by the eleven brokerages that are presently covering the stock, MarketBeat Ratings...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS...

Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 4,607.1% during the second quarter, according to its most recent 13F filing with the Securities...

Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS

Panagora Asset Management Inc. acquired a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing...

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Current Price	$12.56
Prev Close	$12.50
Open	$12.48
Dividend Yield	0.00%
50-Day Moving Average	$12.75
Beta	1.24
Avg. Volume	1.22M
PE Ratio	-5.85

52-Week High	$13.29
52-Week Low	$3.56
Market Capitalization	$718.13M
EPS (Annual)	-$1.68
Price to Book	5.15
Revenue Per Employee	$0.00

ATXSAstria Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATXS News